Q 2 2 0 2 6 E A R N I N G S S U M M A R Y D E C E M B E R 1 6 , 2 0 2 5 000000 0072CE D29F13 333333 666666 880000 NEGATIVES CPG BPG W O R T H I N G T O N E N T E R P R I S E S : P O W E R P O I N T T E M P L A T E V 2 . 0 J A N U A R Y 2 0 2 5 Notes to Investors FORWARD-LOOKING STATEMENTS. Selected statements in this presentation constitute "forward-looking statements," as that term is used in the Private Securities Litigation Reform Act of 1995 (the "Act"). Worthington Enterprises, Inc. (the "Company" or " ...

Summary of BofA December Global Fund Manager Survey Industry Overview - The survey reflects the sentiment of global fund managers regarding macroeconomic conditions, asset allocation, and investment strategies as of December 2025. Key Points Macro & Economic Outlook - **Macro Optimism**: The macro optimism is at its highest since August 2021, with 57% of respondents predicting a soft landing for the economy, 37% expecting no landing, and only 3% anticipating a hard landing [2][19] - **Profit Expectations**: Net profit expectations rose to 29%, the highest since August 2021, indicating a positive outlook on global profits [26] - **Liquidity Conditions**: Rated as the third best in the past 17 years, with 61% of investors rating liquidity conditions as positive, the highest since September 2021 [41][43] Asset Allocation Trends - **Cash Levels**: Cash levels dropped to a record low of 3.3%, down from 3.7%, indicating a strong shift towards risk assets [1][103] - **Equity and Commodity Allocation**: Allocation to equities rose to a net 42% overweight (OW), the highest since December 2024, while commodities reached a net 18% OW, the highest since September 2022 [16][55] - **Sector Rotation**: Significant rotation into US stocks, technology, and materials, while reducing exposure to bonds, healthcare, and staples [4][60] Investment Risks and Concerns - **AI Bubble**: Identified as the biggest tail risk by 38% of investors, with concerns about overinvestment in AI-related capital expenditures [31][29] - **Credit Event Sources**: 40% of investors believe private equity/private credit is the most likely source of a credit event, followed by AI hyperscaler capex at 29% [34][36] Crowded Trades - **Most Crowded Trades**: "Long Magnificent 7" remains the most crowded trade at 54%, followed by "Long Gold" at 29% [37][39] Future Expectations - **Bond Yield Expectations**: 38% of investors expect long-term interest rates to rise, the highest since April 2022 [45] - **Yield Curve Steepening**: 75% of investors anticipate a steepening yield curve in the next 12 months [48] Regional and Sector Allocations - **US Equities**: Net 6% overweight in US equities, the highest since February 2025 [145] - **Underweight Sectors**: Significant underweight positions in energy (26% UW) and consumer staples (20% UW) [56][172] Conclusion - The December survey indicates a strong bullish sentiment among fund managers, with significant shifts towards equities and commodities, while concerns about potential risks, particularly related to AI and credit events, remain prevalent. The overall outlook suggests a cautious optimism as investors navigate the current economic landscape.

Summary of Asia Fund Manager Survey Industry Overview - **Industry**: Asia Pacific Financial Markets - **Survey Period**: December 5 - December 11, 2025 - **Participants**: 238 fund managers with a total of $550 billion in assets under management (AUM) [11] Key Insights Economic Growth Expectations - Global growth expectations reached a four-year high, while Asia Pacific ex-Japan economic prospects are near one-year highs [1][14] - Japan's growth outlook is at a survey peak, indicating strong investor confidence [1] Market Sentiment - Investors maintain a positive market bias but have moderated return expectations due to high valuations [2] - Japan is the most favored market, consistently topping preference rankings since October 2023 [3][50] - China’s growth momentum has stalled, with investors awaiting signs of stimulative policy before increasing exposure [4][28] Sector Preferences - In Japan, banks and semiconductors are favored sectors, driven by rising long-term rates and AI themes [3][48] - In Asia Pacific ex-Japan, tech hardware, semiconductors, and software are the most preferred sectors, while real estate and energy are out of favor [53][54] Investment Themes - Popular investment themes in China include AI, semiconductors, and internet sectors, while green economy and travel have lost favor [55][56] - Korea's 'Corporate Value-Up Program' has garnered positive sentiment post-election [57] Corporate Profit Expectations - A net 41% of fund managers expect stronger corporate profits in the Asia Pacific ex-Japan region, the highest since October 2024 [20][27] - Consensus earnings estimates are not considered high, indicating potential for future upgrades [27] Valuation Concerns - There is a perception that Asia Pacific ex-Japan equities are moderately overvalued due to a significant rally year-to-date [23][25] - Investors are cautious about potential returns given the ~50% rally since April lows [3] China’s Economic Outlook - The outlook for China has stabilized, with a net 3% of investors expecting a stronger economy, a shift from 29% expecting a weaker economy last month [28] - Long-term prospects for China are improving, nearing a three-year high, with 45% of investors believing the equity market is in a structural de-rating process [30][31] Monetary Policy Expectations - There are calls for easing monetary policy in China as consumer and business confidence begins to improve [32][34] - 83% of fund managers expect easier monetary policy in China over the next 12 months [34] Additional Insights - Household risk appetite in China is waning, with a shift towards savings over investments, leading to underweight allocations [4][36] - Japan's economic outlook is overwhelmingly positive, with virtually no investors expecting a weaker economy in the next 12 months [38][39] - Key themes for Japan equities include earnings growth, corporate governance reforms, and Bank of Japan policy normalization [44][45] This summary encapsulates the key findings and insights from the Asia Fund Manager Survey, highlighting the current sentiment and expectations within the Asia Pacific financial markets.

INVESTOR UPDATE For personal use only 17 December 2025 Important information All references to '$' throughout this presentation refer to Australian Dollars, unless marked otherwise. This presentation is in summary form and is not necessarily complete. It should be read together with the Company's Annual Report for 30 June 2025 including the Appendix 4E, the Appendix 4D and 2025 Interim Results, and other announcements lodged with the Australian Securities Exchange, which are available at www.asx.com.au. Thi ...

December 16, 2025 1 Forward-Looking Statements Neurocrine Biosciences R&D Day 2025 In addition to historical facts, this presentation contains forward-looking statements that involve a number of risks and uncertainties. These statements include, but are not limited to, statements related to: our business strategy, objectives, and future development plans; the benefits to be derived from our products and product candidates; the value our products and/or our product candidates may bring to patients; the conti ...

R&D Leadership and Organization - Sanofi is building a skilled and thoughtful R&D leadership team and organization[5, 6, 7, 106] - The company is strengthening capabilities across research, translational medicines, development, medical, regulatory affairs, and digital[106] Pipeline Highlights and Approvals - Sanofi achieved three new medicine and vaccine approvals in 2025: Qfitlia, Wayrilz, and Nuvaxovid[12, 13, 106] - Dupixent showed benefit across relevant endpoints in Bullous pemphigoid, with 12.2% difference in patients achieving sustained remission compared to placebo + OCS and 27.8% difference in patients with ≥4-point improvement in PP-NRS[20, 21] - Dupixent clinically meaningfully improved radiographic, endoscopic, and symptoms of Allergic fungal rhinosinusitis, with lower proportion of patients receiving SCS treatment and/or surgery[24] - Amlitelimab (OX40L mAb) in AD: first phase 3 study met primary and key secondary endpoints, showing clinically meaningful improvement in skin clearance and disease severity[26] - Brivekimig (TNFaxOX40L Nanobody®) in HS: phase 2a study achieved primary objective, with 54% of participants achieving HiSCR75[28, 29] - Itepekimab (IL33 mAb) in COPD: AERIFY-1 study showed a significant reduction in moderate or severe exacerbations of 27.1% at Week 52 with Q2W dosing across EOS level[38] - Duvakitug (TL1A mAb) in CD/UC: positive and encouraging phase 2b data presented at ECCO 2025, with 48% clinical remission in Crohn's disease high dose group[46, 47] - Fluzone HD demonstrated superior protection vs standard-dose influenza vaccines against hospitalization in older adults, including a -31.9% reduction in laboratory confirmed influenza hospitalization[75] - Monovalent RSV (mRNA) vaccine showed 74.9% efficacy against RSV LRTD in a phase 2 study[80] Pipeline Replenishment and Digital Transformation - Sanofi is progressing on pipeline entries augmented by strategic business development[107] - The R&D digital plan aims at reducing cycle times across the R&D value chain by more than 40%[94, 95, 107] Upcoming News Flow - Sanofi anticipates >15 regulatory decisions, >30 regulatory submissions, and >15 phase 3 data readouts in 2026 and 2027[108]

Summary of ReNew Energy Global Conference Call Company Overview - **Company**: ReNew Energy Global (NasdaqGS:RNW) - **Date of Call**: December 16, 2025 Key Points Industry Context - The call addressed the recent developments regarding a consortium involving ReNew Energy and its potential acquisition discussions, particularly focusing on the withdrawal of Masdar from the consortium [4][5]. Core Insights - **Masdar's Withdrawal**: Masdar has officially withdrawn from the consortium, leading to the termination of discussions regarding the proposed transaction. This decision was unexpected and disappointing for ReNew, especially after a year of negotiations and due diligence [4][5][12]. - **Shareholder Confidence**: Despite Masdar's exit, major shareholders CPPIB and ADIA have reaffirmed their confidence in ReNew's business and growth prospects. The company remains committed to delivering value for all shareholders [5][6]. - **Financial Position**: ReNew maintains a robust liquidity position with over $1 billion in cash. The company’s portfolio is fully funded through internal cash flows and capital recycling [6][7]. - **Growth Guidance**: ReNew has reaffirmed its megawatt and EBITDA guidance for the year, indicating continued business growth and a decline in leverage [7][8]. Strategic Considerations - **Future Plans**: The board is evaluating options for realizing value from various parts of the business and will develop a plan moving forward. The leadership team is prepared for alternative strategies following the consortium's dissolution [15][16]. - **Capital Allocation**: The management is considering various strategic options, including potential share repurchases, although no immediate discussions are underway regarding new offers from other shareholders [14][22]. - **Funding and Growth Strategy**: ReNew plans to continue its growth trajectory, targeting an annual capacity of 2 to 3 GW. Funding will come from internal growth and capital recycling, with no reliance on external capital infusion from the failed transaction [32][41]. Market Reaction - Following the announcement of Masdar's withdrawal, there was a notable decline in ReNew's share price. Management expressed confidence that the market will eventually recognize the company's true value [18][52]. Additional Insights - **Operational Performance**: The company is meeting all operational deliverables for the year and does not foresee issues in raising external funding for its current pipeline [16][46]. - **Long-term Strategy**: The board emphasizes the importance of execution in a rapidly growing market and maintains confidence in the management team to deliver long-term shareholder value [51][52]. Conclusion ReNew Energy Global is navigating a challenging situation following the withdrawal of a key consortium member. However, the company remains financially strong and committed to its growth strategy, with plans to communicate further updates to shareholders in the coming months.

Vice President of Investor Relations Reporting Disclaimer This presentation contains, in addition to historical information, certain "forward-looking statements" (within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended), that are based on our current assumptions, expectations and projections about future performance and events and relate to, among other matters, our future financial performance, our business strategy, in ...

Financial Performance - Q3 2025 - Net loss was $10.1 million, compared to a net loss of $28.2 million in the prior year's third quarter[12] - Reported EPS loss was $0.29, with an adjusted EPS loss of $0.23, after adjusting for a tax valuation allowance of $2.0 million[12] - Adjusted EBITDA increased by $5.5 million year-over-year to ($0.7) million[12] - Inventory decreased by $39.2 million, a 17.0% reduction compared to the previous year[12] Balance Sheet and Liquidity - Cash and cash equivalents totaled $8.2 million, with net liquidity at $88.6 million[12] - Debt to Capital ratio is 22.0%[19] - The Asset Based Lending Agreement extends to 2030 and provides for borrowings of up to $125.0 million[21] Fiscal Year 2025 Outlook - Adjusted EBITDA guidance range is affirmed at the higher end, between $23 million and $25 million, compared to the previous range of $20 million to $25 million[12] - Net sales guidance is updated to a range of $555 million to $565 million, compared to the previous guidance of $570 million to $595 million[12] - Capital expenditures are affirmed at $17 million[12] Capital Expenditures Initiatives - The company is investing in capital expenditures for 15 new stores, technology roadmap, website re-platform, etc[27]

Financial Data and Key Metrics Changes - In Q4, net revenue increased 79% to CAD 80.1 million from CAD 44.7 million in the same prior year period [15] - Full-year fiscal 2025 net revenue increased 62% to CAD 259.2 million from CAD 159.8 million in the prior year [15] - Adjusted gross profit for Q4 increased 85% to CAD 30.6 million versus CAD 16.5 million in Q4 last year [16] - Adjusted EBITDA set a company record in fiscal 2025, with Q4 adjusted EBITDA of CAD 9.8 million, an increase of 72% sequentially and 69% year-over-year [20] - The net loss for Q4 was CAD 38 million, compared to a net loss of CAD 5.4 million in the same prior year period [22] Business Line Data and Key Metrics Changes - The acquisition of Motif Labs contributed significantly to growth without market share dilution [4] - The company achieved record international sales of CAD 26.3 million in fiscal 2025, a 171% increase versus the prior year [10] - Adjusted gross margin in Q4 rose by 400 basis points over Q3 to 38% [17] Market Data and Key Metrics Changes - Organigram holds the number one market position in Canada with 11.9% market share in fiscal 2025 [6] - The company ranked first in Ontario, British Columbia, and Alberta, and fourth in Quebec [7] - Market share in New Brunswick reached 34.2%, Newfoundland 23.7%, Saskatchewan 14.9%, and Nova Scotia 12.2% [7] Company Strategy and Development Direction - The company aims to increase the margin profile of its domestic product mix while optimizing operational footprint for capacity and throughput [9] - Plans to launch new products, including coated infused pre-rolls and beverages, to meet evolving consumer needs [9] - The focus on international expansion includes launching branded vapes and gummies in Australia [34] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in continued growth supported by a stronger platform and expanding international opportunities [26] - The company anticipates strong net revenue growth exceeding CAD 300 million in fiscal 2026 [24] - Management is monitoring U.S. regulatory changes that could impact the hemp-derived THC market but does not expect a material adverse economic impact [12] Other Important Information - The company received a CAD 2 million grant from Opportunities New Brunswick to support facility enhancements [6] - The Jupiter Fund currently has CAD 59 million available for deployment to leverage opportunities in markets outside of Canada [13] - The company is awaiting a determination on its EU-GMP application submitted in October 2025 [12] Q&A Session Summary Question: International growth expectations and supply-demand dynamics - Management indicated that they are starting to realize increased capacity and are well-positioned for fiscal 2026, particularly in Germany [32] Question: Gross margin expectations for fiscal 2026 - Management expects continued improvement in gross margin driven by operational improvements and synergies from the Motif acquisition [36] Question: Contribution of Motif synergies versus cultivation improvements to margin improvement - Management stated that the majority of margin improvement will come from operational improvements in cultivation rather than solely from Motif synergies [46] Question: Capital expenditure plans for the next year - Management plans to keep capital expenditures modest for fiscal 2026, expecting to spend less than CAD 10 million [47]